Keya Medical Closes RMB 300 Million Series D Funding Round

Keya Medical, a leading domestic AI medical device company, announced that it has received more than 300 million yuan in D round of financing. This round of financing is jointly invested by shareholders such as CICC Capital, Shanghai Artificial Intelligence Industry Fund, Gaozu Assets, and IN Capital.

This investment is the fourth large-scale funding round that Keya Medical has completed in just nine months. In February, Keya Medical received a strategic investment led by Kunlun Internet Smart Fund, and a joint co-investment by Growth FOF, and Alwin Capital. In August, Keya Medical was awarded an additional $22 million in a Series B+ funding round. 

Despite the impact of the COVID-19 pandemic, Keya Medical has continued to accelerate progress in medical AI. The company’s flagship product, DEEPVESSEL FFR, became the first AI software medical device to receive National Medical Products Administration approval in January, and is the only CT-derived FFR product approved for clinical use in China. Keya Medical has adhered to the product development principle of developing solutions that are based on “real clinical needs,” using funds to bring products to market that empower both clinicians and patients.

Keya Medical will use this investment to support the global commercial development of Keya Medical’s products, providing an important driving force for subsequent product development and market expansion. Keya Medical welcomes collaboration partners around the world to help support progress.

Dr. Song Qi, CEO of Keya Medical, said: "The commercialization of the artificial intelligence medical device industry, we believe that the main difficulties come from the two aspects of'standard recognition and value recognition', and Keya Medical has also initially solved it because of insights. Only with these two major difficulties can the capital be paid attention to and reap the current achievements."